Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

CONCLUSIONS: Regorafenib combined with toripalimab has a promising effect in the third-line and beyond treatment of advanced colorectal cancer. In the early use of combination therapy, excision of primary lesions can have a positive impact in regorafenib and toripalimab combination. This treatment-related adverse reactions are tolerant in combined therapy.PMID:34603452 | PMC:PMC8486501 | DOI:10.1155/2021/9959946
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research